Marcel G. Smits
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marcel G. Smits has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Ingeborg Marianne Van Geijlswijk
Veterinary and Comparative Pharmacology, Department of Population Health Sciences, Faculty of Veterinary Medicine Utrecht University Utrecht the Netherlands
2 shared publications A. M. L. Coenen
University of Nijmegen
1 shared publicationAnne Marie. Meijer
1 shared publication- Anneke P.H.M. Maas
GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
1 shared publication Anton M.L. Coenen
1 shared publication- Carin Ma Rademaker
Department of Clinical Pharmacy, Division of Laboratory and Pharmacy, University Medical Centre Utrecht, Utrecht 3584 CX, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 2 March 2018
- Published by MDPI AG in Healthcare
- Vol. 6 (1) , 23
Long-Term Melatonin Therapy for Adolescents and Young Adults with Chronic Sleep Onset Insomnia and Late Melatonin Onset: Evaluation of Sleep Quality, Chronotype, and Lifestyle Factors Compared to Age-Related Randomly Selected Population Cohorts
The extent of continuance of melatonin therapy initiated in pre-pubertal children with chronic sleep onset insomnia (CSOI) was investigated in young adult life. Sleep timing, sleep quality, adverse events, reasons for cessation of therapy, and patient characteristics with regard to therapy regimen, chronotype and lifestyle factors possibly influencing sleeping behavior were assessed. With an online survey using questionnaires (Pittsburgh Sleep Quality Index, Insomnia Severity Index, Morningness-Eveningness Questionnaire, and Munich Chronotype Questionnaire), outcomes were measured and compared with age-related controls. These controls were extracted from published epidemiological research programs applying the same questionnaires. At the moment of the survey, melatonin was still continued by 27.3% of the patients, with a mean treatment duration of 10.8 years. The overall average treatment duration was 7.1 years. Sleep quality of both discontinued and persistent melatonin users did not deviate from controls. Sleep timing and chronotype scores indicated evening type preference in all responders. Adverse events were scarce but the perceived timing of pubertal development suggested a tendency towards delayed puberty in former and current users of melatonin. This study may underestimate the number of children that are able to stop using melatonin due to the response rate (47.8%) and appeal for continuing users. Sleep timing parameters were based on self-reported estimates. Control populations were predominantly students and were of varying nationalities. The statistical power of this study is low due to the limited sample size. Melatonin therapy sustained for 7.1 years does not result in substantial deviations of sleep quality as compared to controls and appears to be safe. The evening type preference suggests a causal relation with CSOI. This study shows that ten years after initiation of treatment with melatonin for CSOI, approximately 75% of the patients will have normal sleep quality without medication.
- 2 March 2018
- Published by MDPI AG in Healthcare
- Vol. 6 (1) , 23
Open AccessLong-Term Melatonin Therapy for Adolescents and Young Adults with Chronic Sleep Onset Insomnia and Late Melatonin Onset: Evaluation of Sleep Quality, Chronotype, and Lifestyle Factors Compared to Age-Related Randomly Selected Population Cohorts
The extent of continuance of melatonin therapy initiated in pre-pubertal children with chronic sleep onset insomnia (CSOI) was investigated in young adult life. Sleep timing, sleep quality, adverse events, reasons for cessation of therapy, and patient characteristics with regard to therapy regimen, chronotype and lifestyle factors possibly influencing sleeping behavior were assessed. With an online survey using questionnaires (Pittsburgh Sleep Quality Index, Insomnia Severity Index, Morningness-Eveningness Questionnaire, and Munich Chronotype Questionnaire), outcomes were measured and compared with age-related controls. These controls were extracted from published epidemiological research programs applying the same questionnaires. At the moment of the survey, melatonin was still continued by 27.3% of the patients, with a mean treatment duration of 10.8 years. The overall average treatment duration was 7.1 years. Sleep quality of both discontinued and persistent melatonin users did not deviate from controls. Sleep timing and chronotype scores indicated evening type preference in all responders. Adverse events were scarce but the perceived timing of pubertal development suggested a tendency towards delayed puberty in former and current users of melatonin. This study may underestimate the number of children that are able to stop using melatonin due to the response rate (47.8%) and appeal for continuing users. Sleep timing parameters were based on self-reported estimates. Control populations were predominantly students and were of varying nationalities. The statistical power of this study is low due to the limited sample size. Melatonin therapy sustained for 7.1 years does not result in substantial deviations of sleep quality as compared to controls and appears to be safe. The evening type preference suggests a causal relation with CSOI. This study shows that ten years after initiation of treatment with melatonin for CSOI, approximately 75% of the patients will have normal sleep quality without medication.
- Open Access
Low parental melatonin levels increases autism spectrum disorder risk in children
Low melatonin levels are a frequent finding in autism spectrum disorder (ASD) patients. Melatonin is important for normal neurodevelopment and embryonic growth and highly effective in protecting DNA from oxidative damage. Melatonin deficiency, possibly due to low CYP1A2 activity, could be an etiologic factor. As the fetus does not produce melatonin, low maternal melatonin levels should be involved. We measured 6-sulfatoxymelatonin in urine of 60 mothers of a child with ASD that attended our sleep clinic for people with an intellectual disability (ID), and asked for coffee consumption habits, as these are known to be related to CYP1A2 activity. 6-Sulfatoxymelatonin levels were significantly lower in mothers than in controls ( p = 0.005), as well as evening coffee consumption ( p = 0.034). Abbreviations: ASD Autism spectrum disorder ID intellectual disability 6-SM 6–sulfatoxymelatonin
Open AccessLow parental melatonin levels increases autism spectrum disorder risk in children
Low melatonin levels are a frequent finding in autism spectrum disorder (ASD) patients. Melatonin is important for normal neurodevelopment and embryonic growth and highly effective in protecting DNA from oxidative damage. Melatonin deficiency, possibly due to low CYP1A2 activity, could be an etiologic factor. As the fetus does not produce melatonin, low maternal melatonin levels should be involved. We measured 6-sulfatoxymelatonin in urine of 60 mothers of a child with ASD that attended our sleep clinic for people with an intellectual disability (ID), and asked for coffee consumption habits, as these are known to be related to CYP1A2 activity. 6-Sulfatoxymelatonin levels were significantly lower in mothers than in controls ( p = 0.005), as well as evening coffee consumption ( p = 0.034). Abbreviations: ASD Autism spectrum disorder ID intellectual disability 6-SM 6–sulfatoxymelatonin
- 2 September 2015
- Published by Taylor & Francis in Behavioral Sleep Medicine
- Vol. 14 (5) , 480-488
Prevalence of Restless Legs Syndrome in Adult ADHD and Its Subtypes
In this observational cross-sectional study, 49 subjects were assessed for sleep disorders and for ADHD symptoms. Thirty-six received an ADHD diagnosis (29: combined type (ADHD-C); 7: inattentive type). An RLS and RLS symptoms prevalence of 34.5% was found, with a higher prevalence rate in the ADHD-C subgroup, although not significantly (p = 0.066). RLS symptoms were correlated with particularly hyperactivity-impulsivity (ρ = 0.742; p: 0.000). ADHD patients with positive RLS scores reported higher scores on the ADHD-Rating scale compared with patients with negative RLS scores (Z: −2.968, p = 0.003), mainly due to higher hyperactivity-impulsivity scores (Z: −3.145; p = 0.002). Our findings show that clinicians need to be aware of RLS among adult ADHD patients, particularly those with severe hyperactivity-impulsivity symptoms.
- 2 September 2015
- Published by Taylor & Francis in Behavioral Sleep Medicine
- Vol. 14 (5) , 480-488
Prevalence of Restless Legs Syndrome in Adult ADHD and Its Subtypes
In this observational cross-sectional study, 49 subjects were assessed for sleep disorders and for ADHD symptoms. Thirty-six received an ADHD diagnosis (29: combined type (ADHD-C); 7: inattentive type). An RLS and RLS symptoms prevalence of 34.5% was found, with a higher prevalence rate in the ADHD-C subgroup, although not significantly (p = 0.066). RLS symptoms were correlated with particularly hyperactivity-impulsivity (ρ = 0.742; p: 0.000). ADHD patients with positive RLS scores reported higher scores on the ADHD-Rating scale compared with patients with negative RLS scores (Z: −2.968, p = 0.003), mainly due to higher hyperactivity-impulsivity scores (Z: −3.145; p = 0.002). Our findings show that clinicians need to be aware of RLS among adult ADHD patients, particularly those with severe hyperactivity-impulsivity symptoms.
- 1 July 2009
- Published by Wiley in Journal of Pineal Research
- Vol. 47 (1) , 1-7
Long‐term follow‐up of melatonin treatment in children with ADHD and chronic sleep onset insomnia
Abstract: We conducted this study to assess long‐term melatonin treatment course, effectiveness and safety in children with attention‐deficit/hyperactivity disorder (ADHD) and chronic sleep onset insomnia (CSOI). This was conducted by means of a structured questionnaire for the parents. The subjects of this study consisted of participants who previously participated in a randomised clinical trial on melatonin efficacy. The response rate was 93% (94/101). The mean time to follow up was 3.7 yr. No serious adverse events or treatment related co‐morbidities were reported. Sixty‐five percent of the children still used melatonin daily and 12% occasionally. Temporal discontinuation of treatment resulted in a delay of sleep onset in 92% of the children. Nine percent of the children could discontinue melatonin completely because of improvement of sleep onset insomnia. Long‐term melatonin treatment was judged to be effective against sleep onset problems in 88% of the cases. Improvement of behaviour and mood was reported in 71% and 61% respectively. We conclude that melatonin remains an effective therapy on the long term for the treatment of CSOI in children with ADHD and has no safety concerns regarding serious adverse events or treatment related co‐morbidity. Discontinuation of melatonin treatment usually leads to a relapse of sleep onset insomnia and in resuming melatonin treatment, even after several years of treatment.
- 1 July 2009
- Published by Wiley in Journal of Pineal Research
- Vol. 47 (1) , 1-7
Long‐term follow‐up of melatonin treatment in children with ADHD and chronic sleep onset insomnia
Abstract: We conducted this study to assess long‐term melatonin treatment course, effectiveness and safety in children with attention‐deficit/hyperactivity disorder (ADHD) and chronic sleep onset insomnia (CSOI). This was conducted by means of a structured questionnaire for the parents. The subjects of this study consisted of participants who previously participated in a randomised clinical trial on melatonin efficacy. The response rate was 93% (94/101). The mean time to follow up was 3.7 yr. No serious adverse events or treatment related co‐morbidities were reported. Sixty‐five percent of the children still used melatonin daily and 12% occasionally. Temporal discontinuation of treatment resulted in a delay of sleep onset in 92% of the children. Nine percent of the children could discontinue melatonin completely because of improvement of sleep onset insomnia. Long‐term melatonin treatment was judged to be effective against sleep onset problems in 88% of the cases. Improvement of behaviour and mood was reported in 71% and 61% respectively. We conclude that melatonin remains an effective therapy on the long term for the treatment of CSOI in children with ADHD and has no safety concerns regarding serious adverse events or treatment related co‐morbidity. Discontinuation of melatonin treatment usually leads to a relapse of sleep onset insomnia and in resuming melatonin treatment, even after several years of treatment.
- 12 January 2006
- Published by Wiley in European Journal of Neurology
- Vol. 13 (1) , 55-60
Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion
The effect of melatonin, a chronobiotic drug, was explored in 29 patients with chronic fatigue syndrome (CFS) and Dim Light Melatonin onset (DLMO) later than 21.30 hours, reflective of delayed circadian rhythmicity. The patients took 5 mg of melatonin orally, 5 h before DLMO during 3 months. Their responses to the checklist individual strength (CIS), a reliable questionnaire measuring the severity of personally experienced fatigue, were assessed twice with a 6‐week interval immediately before the treatment and once after 3 months treatment. In the pre‐treatment period the fatigue sub‐score improved significantly. After treatment, the total CIS score and the sub‐scores for fatigue, concentration, motivation and activity improved significantly. The sub‐score fatigue normalized in two of the 29 patients in the pre‐treatment period and in eight of 27 patients during treatment. This change was significant. In the patients with DLMO later than 22.00 hours (n = 21) the total CIS score and the sub‐scores for fatigue, concentration and activity improved significantly more than in the patients (n = 8) with DLMO earlier than 22.00 hours. Melatonin may be an effective treatment for patients with CFS and late DLMO, especially in those with DLMO later than 22.00 hours.
- 12 January 2006
- Published by Wiley in European Journal of Neurology
- Vol. 13 (1) , 55-60
Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion
The effect of melatonin, a chronobiotic drug, was explored in 29 patients with chronic fatigue syndrome (CFS) and Dim Light Melatonin onset (DLMO) later than 21.30 hours, reflective of delayed circadian rhythmicity. The patients took 5 mg of melatonin orally, 5 h before DLMO during 3 months. Their responses to the checklist individual strength (CIS), a reliable questionnaire measuring the severity of personally experienced fatigue, were assessed twice with a 6‐week interval immediately before the treatment and once after 3 months treatment. In the pre‐treatment period the fatigue sub‐score improved significantly. After treatment, the total CIS score and the sub‐scores for fatigue, concentration, motivation and activity improved significantly. The sub‐score fatigue normalized in two of the 29 patients in the pre‐treatment period and in eight of 27 patients during treatment. This change was significant. In the patients with DLMO later than 22.00 hours (n = 21) the total CIS score and the sub‐scores for fatigue, concentration and activity improved significantly more than in the patients (n = 8) with DLMO earlier than 22.00 hours. Melatonin may be an effective treatment for patients with CFS and late DLMO, especially in those with DLMO later than 22.00 hours.
- 1 November 2003
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 42 (11) , 1286-1293
Melatonin Improves Health Status and Sleep in Children With Idiopathic Chronic Sleep-Onset Insomnia: A Randomized Placebo-Controlled Trial
- 1 November 2003
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 42 (11) , 1286-1293
Melatonin Improves Health Status and Sleep in Children With Idiopathic Chronic Sleep-Onset Insomnia: A Randomized Placebo-Controlled Trial
- 1 January 2001
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 21 (12) , 813-820
Melatonin for Chronic Whiplash Syndrome with Delayed Melatonin Onset
- 1 January 2001
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 21 (12) , 813-820
Melatonin for Chronic Whiplash Syndrome with Delayed Melatonin Onset